Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Appointed director
|
Vivani Medical, Inc. (EYES)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/10/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs:
|
"ARTICLE I",
"VIVANI MEDICAL, INC. PLAN OF CONVERSION This Plan of Conversion sets forth certain terms of the conversion of Vivani Medical, Inc. , a California corporation , to a Delaware corporation , pursuant to the terms of the California Corporations Code and the General Corporation Law of the State of Delaware . WITNESSETH: WHEREAS, the California Corporation was incorporated on May 22, 2003; WHEREAS, upon the terms and subject to the conditions set forth in this Plan, and in accordance with Section 1152 of the CCC and Section 265 of the DGCL, the California Corporation will be converted to a Delaware Corporation; WHEREAS, the board of directors of the California Corporation has unanimously determined that the Conversion is advisable and in the best interests of the California Corporation and its s..." |
|
06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
05/15/2023 |
8-K
| Quarterly results
Docs:
|
"Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI May 15, 2023 www.vivani.com",
"VIVANI MEDICAL, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets March 31, 2023 December 31, 2022 ASSETS Current assets: Cash and cash equivalents $ 38,073 $ 45,076 Prepaid expenses and other current assets 2,611 2,452 Total current assets 40,684 47,528 Property and equipment, net 1,111 1,182 Right-of-use assets 1,148 779 Restricted cash 1,366 1,366 Deposits and other assets 271 275 Total assets $ 44,580 $ 51,130 LIABILITIE S AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 746 $ 1,177 Accrued expenses 2,114 2,358 Litigation accrual 1,675 1,675 Accrued compensation expense 415 657 Current operating lease liabilities 913 955 Total current liabilities 5,863 6,822 Long term operating lease liabilities 349 — Total liabilities 6,212 6,822 Commitments and contingencie..." |
|
03/21/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...
Docs:
|
"TRANSITION FUNDING, SUPPORT AND SERVICES AGREEMENT This TRANSITION FUNDING, SUPPORT AND SERVICES AGREEMENT , dated as of March 19, 2023 , is by and between Vivani Medical, Inc., a California corporation , and Cortigent, Inc., a Delaware corporation . Parent and Cortigent may be referred to herein individually as a “ Party ” and collectively as the “ Parties ”. R E C I T A L S WHEREAS, Cortigent is presently a wholly owned subsidiary of Parent formerly known as Second Sight Medical Products, Inc. ; WHEREAS Cortigent includes the personnel, technologies, intellectual property and other assets that formerly comprised Second Sight; WHEREAS, Cortigent is a pioneer in developing targeted neurostimulation systems to provide artificial vision to blind persons and is developing new medical device s...",
"Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI March 21, 2023 www.vivani.com",
"Investor Contact:" |
|
01/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
12/15/2022 |
8-K
| Quarterly results |
11/28/2022 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results
Docs:
|
"VIVANI MEDICAL, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets September 30, December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 51,684 $ 2,178 Prepaid expenses and other current assets 2,779 291 Total current assets 54,463 2,469 Property and equipment, net 1,250 1,173 Right-of-use assets 1,050 1,611 Deposits and other assets 259 200 Total assets $ 57,022 $ 5,453 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,969 $ 281 Accrued expenses 1,853 895 Accrued compensation expense 555 — Current operating lease liabilities 1,243 910 Total current liabilities 5,620 2,086 Long term operating lease liabilities 42 902 Total liabilities 5,662 2,988 Commitments and contingencies Stockholders’ equity: Preferred stock, no par value, 10,000 ..." |
|
10/17/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
09/23/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/02/2022 |
8-K
| Resignation/termination of a director, Appointed a new director
Docs:
|
"WAIVER OF CLOSING CONDITION",
"California Secretary of State Business Programs Division 1500 11th Street, Sacramento, CA 95814 Request Type: Entity Name: Entity No.: Entity Type: Issuance Date: Copies Requested: Receipt No.: Certified Copies SECOND SIGHT MEDICAL PRODUCTS, INC. 08/25/2022 1 CALIFORNIA 2536744 Stock Corporation - CA - General 002438198 Formed In: Certificate No.: 040203220 Document Listing Reference # Date Filed Filing Description Number of Pages B1050-1683 08/25/2022 Amendment 1 ** **** ****** ******** End of list ******** ****** **** ** I, SHIRLEY N. WEBER, PH.D., California Secretary of State, do hereby certify on the Issuance Date, the attached document referenced above are true and correct copies and were filed in this office on the date indicated above. IN WITNESS WHEREOF, I execute this certificate...",
"Nano Precision Medical, Inc. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION" |
|
08/18/2022 |
8-K
| Quarterly results |
08/05/2022 |
8-K
| Quarterly results |
07/29/2022 |
8-K
| Quarterly results |
07/18/2022 |
8-K
| Quarterly results |
06/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
|
"Waiver of Available Cash Requirement This waiver is made on June 15, 2022, and applies to the Agreement and Plan of Merger between Second Sight Medical Product, Inc. and Nano Precision Medical, Inc., dated February 4, 2022 . Whereas the Merger agreement requires that the Available Cash shall not be less than $64,000,000, less the amount of any advance made by SSMP to the Company for working capital; and Whereas SSMP will likely not meet the stated Available Cash requirement due to delays in completing the merger. Therefore, the parties agree as follows: 1. Capitalized terms not herein defined, have the meaning set forth in the Merger Agreement. 2. Company waives the Available Cash requirement, provided that, the Available Cash remains $63,000,000 less the amount of any advance made by SSMP..." |
|
06/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/07/2022 |
8-K
| Quarterly results |
02/07/2022 |
8-K
| Quarterly results |
08/04/2021 |
8-K
| Other Events |
07/02/2021 |
8-K
| Quarterly results |
06/25/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
06/23/2021 |
8-K
| Quarterly results |
06/21/2021 |
8-K
| Quarterly results |
06/04/2021 |
8-K
| Quarterly results |
06/03/2021 |
8-K
| Quarterly results |
06/01/2021 |
8-K
| Quarterly results |
04/07/2021 |
8-K
| Quarterly results |
04/06/2021 |
8-K
| Quarterly results |
04/05/2021 |
8-K
| Quarterly results |
04/01/2021 |
8-K
| Quarterly results |
03/26/2021 |
8-K
| Quarterly results |
03/24/2021 |
8-K
| Quarterly results |
03/05/2021 |
8-K
| Quarterly results |
|
|
|